Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26639
Title: T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection.
Austin Authors: Kuzich, James A;Kankanige, Yamuna;Guinto, Jerick;Ryland, Georgina;McBean, Michelle;Wong, Eric ;Koldej, Rachel;Collins, Jenny;Westerman, David;Ritchie, David;Blombery, Piers
Affiliation: Clinical Haematology
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
University of Melbourne, Parkville, VIC, Australia
Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia
ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, VIC, Australia
Issue Date: Oct-2021
Date: 2021-05-24
Publication information: Bone Marrow Transplantation 2021; 56(10): 2582-2590
Abstract: Identification of patients at risk of initial & recurrent cytomegalovirus (CMV) reactivation following allogeneic stem cell transplant (alloSCT) may help guide prophylactic strategies. T-cell receptor beta (TRB) deep sequencing was used to identify and enumerate the T-cell repertoire harbouring TRB sequences with annotated specificity to CMV (pubCMVrep), as well as the overall T-cell receptor (TCR) repertoire diversity at day +30 & day +60 post-alloSCT for 65 patients. T-cells harbouring TRB sequences with annotated specificity for CMV were identifiable in all patients. 56% of patients required CMV treatment and 23% of the cohort developed recurrent CMV. PubCMVrep size at day +30 was not associated with reactivation, however amongst patients with antecedent CMV viremia a low day +60 pubCMVrep was associated with a greater incidence of recurrent CMV (75% vs. 21%, HR 6.16, 95% CI 1.29-29.40, P = 0.0008). Moreover, patients with high pubCMVrep only developed recurrent CMV in the setting of GVHD. Low TCR diversity at day +30 was associated with a greater incidence of initial CMV reactivation (71% vs. 22%, HR 5.39, 95% CI 1.70-17.09, p = 0.0002). pubCMVrep and TCR diversity are promising biomarkers to identify patients at risk of initial & recurrent CMV who may benefit from novel prophylactic strategies.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26639
DOI: 10.1038/s41409-021-01354-2
ORCID: 0000-0002-3657-8010
0000-0002-1627-8934
Journal: Bone Marrow Transplantation
PubMed URL: 34031553
Type: Journal Article
Subjects: T cell receptor
allogeneic stem cell transplant
cytomegalovirus
Appears in Collections:Journal articles

Show full item record

Page view(s)

48
checked on Dec 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.